News

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.

Eli Lilly (LLY) keeps setting records, and Wall Street’s rating of its stock keeps increasing as well. On Tuesday, one of JPMorgan’s most closely watched healthcare stock analysts, Chris Schott, who frequently covers Pfizer Inc. (PFE), Eli Lilly, and Teva Pharmaceutical Industries Ltd. ...

In late June 2026, Innovent Biologics announced a distribution and promotion agreement giving it sole commercialization rights for Eli Lilly’s breast cancer drug Verzenios in mainland China, while Lilly retains manufacturing, supply and development responsibilities. At the same time, Eli Lilly received a positive regulatory opinion in Europe for expanding Jaypirca’s use in chronic lymphocytic leukemia, underscoring how partnerships and oncology approvals are broadening the company’s reach...

Healthcare stocks were lower late Wednesday afternoon, with the NYSE Healthcare Index down 0.9% and

The chipmaker signaled a major turn in its business, and the market bought it. Now comes the hard part: proving the rally can last.

The stock has soared 400% in recent years.

Check out the companies making headlines yesterday:

Healthcare stocks declined Wednesday afternoon, with the NYSE Healthcare Index and the State Street

Major US biopharmaceutical companies' performance in the second half of the year is likely to be dri

The pharmaceutical industry is entering a new era where biology and artificial intelligence are converging. Drug discovery, once a slow process measured in years and billions of dollars, is increasingly becoming a data-driven competition. Companies that combine proprietary medical data with AI tools may gain an advantage similar to what technology companies achieved during the ... Wall Street Is Betting on Eli Lilly’s GLP-1 Portfolio — It’s Missing the $1 Trillion Opportunity

For shareholders, the coming year isn't about a small gain or loss but a potential journey to one of two very different destinations.

Eli Lilly (LLY) is expected to deliver Q2 revenue slightly above consensus on stronger-than-anticipa

Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather th

Eli Lilly (LLY) is poised to outpace second-quarter sales consensus estimates as strong volume uptak

Eli Lilly hits another record high as confidence grows in its obesity and diabetes portfolio, with Wall Street still seeing upside despite the rich valuation.

Eli Lilly's next leg of growth may have less to do with how well its weight loss drugs work and more to do with how many people can finally get them.

The Number $8.662 billion. That is what Mounjaro alone generated for Eli Lilly (NYSE:LLY) in the first quarter of 2026, a single product, a single quarter, up 125% year over year. The figure was disclosed in Lilly’s Q1 2026 earnings release on April 30, 2026, an actual reported figure. This key growth driver is what ... This $1,200 Stock Could Be the Next Massive Stock Split Opportunity

A barrage of stocks to watch like Eli Lilly and Deere, show promise, alongside reminders to keep risk management in mind.

Dow Jones futures tumbled as President Donald Trump said the U.S.-Iran ceasefire is "over." Crude oil prices soared.

Wall Street is getting more bullish on the pharma giant's shares.

While one continues reinvesting for growth, the other has rewarded shareholders for 54 years in a row.

Don't sleep on these medical device leaders.

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.8% in the afternoon session after JPMorgan's Chris Schott raised his price target to $1,400 from $1,300, reiterating an Overweight rating.

Eli Lilly (LLY) is back in focus after handing Chinese partner Innovent Biologics full commercial control of breast cancer drug Verzenios, a shift that raises fresh questions about how the stock’s premium valuation stacks up. See our latest analysis for Eli Lilly. Verzenios is only one piece of a much bigger story for Eli Lilly. The stock gave back some ground in the latest session as the share price fell 1.14% to US$1,200.06, yet it is still showing firm momentum with a 30 day share price...

The Nasdaq led the stock market lower Tuesday, as Samsung earnings slammed AI names. Oil prices jumped on U.S.-Iran news.

The stock is down, but it isn't out yet.

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index and the State S

Construction at Pfizer’s former headquarters in Manhattan was halted Tuesday because of crumbling floors and other structural issues. The problems with the building’s renovation, which the company sold about eight years ago for conversion to apartments, are a metaphor of sorts for Pfizer stock, which began Tuesday with the highest yield in the index, at more than 7%. Pfizer stock, which is up 1.6% to $24.10 Tuesday, has been the worst performer among its large-cap U.S. peers during 2026 and over the past 10 years.

Drug stocks got hit hard on Monday in what Jim Cramer called a “vicious rotation,” and the selloff looked like the usual crowded-trade unwind. Investors decided the Mounjaro story was played out. On Tuesday morning’s Mad Dash, Cramer walked through why he thinks that reading is wrong, and he had a fresh JPMorgan note flagging ... Everyone Thinks the Eli Lilly Story Is Played Out. Cramer Thinks They’re Dead Wrong

Good medical care will always be in high demand, which makes some healthcare stocks strong long-term picks.